ADMA Biologics Inc (ADMA)
Profitability ratios
Return on sales
| Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 48.93% | 46.12% | 39.39% | 34.44% | 30.74% | 27.41% | 26.45% | 22.89% | 18.85% | 13.92% | 6.97% | 1.45% | -10.94% | -16.28% | -29.47% | -45.17% | -33.67% | -34.06% | -30.28% | -34.60% |
| Operating profit margin | 30.01% | 25.42% | 15.63% | 8.38% | 0.57% | -8.01% | -13.94% | -25.55% | -35.64% | -46.89% | -61.73% | -72.12% | -91.08% | -106.29% | -131.70% | -153.75% | -137.77% | -136.31% | -124.89% | -141.14% |
| Pretax margin | 19.16% | 11.86% | -1.08% | -10.94% | -9.74% | -19.36% | -26.22% | -42.77% | -53.89% | -66.44% | -83.27% | -88.51% | -108.59% | -126.67% | -155.78% | -179.41% | -166.00% | -164.90% | -151.18% | -164.49% |
| Net profit margin | 17.80% | 10.53% | -1.29% | -10.94% | -9.74% | -19.36% | -26.22% | -42.77% | -53.89% | -66.44% | -83.27% | -88.51% | -108.59% | -126.67% | -155.78% | -179.41% | -166.00% | -164.90% | -151.18% | -164.49% |
The profitability ratios of ADMA Biologics Inc have shown a mixed performance over the past several quarters.
1. Gross Profit Margin: The company's gross profit margin has been increasing steadily, indicating an improvement in its ability to generate revenue after accounting for the cost of goods sold.
2. Operating Profit Margin: ADMA Biologics Inc has shown an upward trend in its operating profit margin, which suggests that the company is becoming more efficient in managing its operating expenses and generating profit from its operational activities.
3. Pretax Margin: The pretax margin has been volatile, with fluctuations in profitability before accounting for taxes. The negative values in some periods indicate that the company's expenses exceeded its revenue.
4. Net Profit Margin: The net profit margin also displays erratic behavior, with some periods showing profitability while others reflecting negative margins. This ratio highlights the company's ability to generate profit after all expenses, including interest and taxes.
In summary, while there have been improvements in gross profit margin and operating profit margin, ADMA Biologics Inc still faces challenges in achieving consistent profitability, as indicated by the fluctuations in pretax and net profit margins. Further analysis of the company's cost structure and revenue generation strategies may provide insights into enhancing overall profitability in the future.
Return on investment
| Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 29.41% | 22.30% | 12.62% | 6.57% | 0.38% | -4.86% | -7.44% | -11.30% | -15.47% | -17.38% | -18.84% | -21.13% | -26.15% | -26.53% | -26.86% | -31.26% | -29.23% | -26.51% | -21.37% | -32.59% |
| Return on assets (ROA) | 17.44% | 9.24% | -1.04% | -8.58% | -6.54% | -11.75% | -13.99% | -18.91% | -23.40% | -24.63% | -25.41% | -25.94% | -31.18% | -31.62% | -31.77% | -36.47% | -35.22% | -32.07% | -25.87% | -37.99% |
| Return on total capital | 34.58% | 26.39% | 15.68% | 8.14% | 0.46% | -5.80% | -8.75% | -13.35% | -19.23% | -20.31% | -21.87% | -24.73% | -31.65% | -30.06% | -30.74% | -35.82% | -32.97% | -29.27% | -23.37% | -43.84% |
| Return on equity (ROE) | 29.38% | 18.48% | -2.37% | -20.89% | -15.07% | -27.45% | -32.74% | -43.37% | -70.05% | -63.93% | -61.67% | -50.75% | -72.39% | -65.96% | -66.56% | -85.83% | -93.73% | -79.89% | -56.53% | -184.32% |
ADMA Biologics Inc's profitability ratios have shown a mixed performance over the past few quarters.
- Operating return on assets (Operating ROA) has shown an improving trend, increasing from 0.38% in Sep 2023 to 29.41% in Sep 2024. This indicates that the company's core operations are becoming more efficient in generating profits from its assets.
- Return on assets (ROA) has also improved from -37.99% in Dec 2020 to 17.44% in Sep 2024. This suggests that the company is generating a higher level of profit relative to its total assets, indicating better asset utilization.
- Return on total capital has shown a similar trend to ROA, increasing from -43.84% in Dec 2019 to 34.58% in Sep 2024. This indicates that the company is effectively utilizing its total capital to generate profits.
- Return on equity (ROE) has fluctuated significantly, ranging from -184.32% in Dec 2020 to 29.38% in Sep 2024. This ratio reflects the company's ability to generate profits from shareholder equity, with the recent increase potentially indicating improved shareholder value.
Overall, while there have been fluctuations in profitability ratios, there appears to be a positive trend in the company's ability to generate profits and efficiently utilize its assets and capital over the analyzed period.